Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling.

PubWeight™: 1.17‹?› | Rank: Top 10%

🔗 View Article (PMC 4467376)

Published in Nat Commun on June 11, 2015

Authors

Marc Zuckermann1, Volker Hovestadt1, Christiane B Knobbe-Thomsen2, Marc Zapatka1, Paul A Northcott3, Kathrin Schramm1, Jelena Belic1, David T W Jones3, Barbara Tschida4, Branden Moriarity4, David Largaespada4, Martine F Roussel5, Andrey Korshunov6, Guido Reifenberger2, Stefan M Pfister3, Peter Lichter1, Daisuke Kawauchi3, Jan Gronych1

Author Affiliations

1: Division of Molecular Genetics, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
2: 1] Department of Neuropathology, Heinrich Heine University Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf, Germany [2] German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, 40225 Düsseldorf, Germany.
3: Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
4: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, USA.
5: Tumor Cell Biology, St Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105, USA.
6: 1] Department of Neuropathology, University of Heidelberg, Im Neuenheimer Feld 220, 69120 Heidelberg, Germany [2] Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 220-221, 69120 Heidelberg, Germany.

Articles citing this

Applications of CRISPR-Cas systems in neuroscience. Nat Rev Neurosci (2015) 1.18

Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice. Nat Commun (2016) 1.00

CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. Sci Rep (2015) 0.98

Creating and evaluating accurate CRISPR-Cas9 scalpels for genomic surgery. Nat Methods (2015) 0.96

Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland. Genes Dev (2016) 0.90

PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype. Nat Commun (2015) 0.86

Tracking and transforming neocortical progenitors by CRISPR/Cas9 gene targeting and piggyBac transposase lineage labeling. Development (2015) 0.86

CRISPR/Cas9-induced disruption of gene expression in mouse embryonic brain and single neural stem cells in vivo. EMBO Rep (2016) 0.83

CRISPR: a versatile tool for both forward and reverse genetics research. Hum Genet (2016) 0.82

Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS. AIDS (2016) 0.82

Annexin A2 Modulates ROS and Impacts Inflammatory Response via IL-17 Signaling in Polymicrobial Sepsis Mice. PLoS Pathog (2016) 0.82

CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways. J Hematol Oncol (2016) 0.82

The present and future of genome editing in cancer research. Hum Genet (2016) 0.81

Rapid tumor induction in zebrafish by TALEN-mediated somatic inactivation of the retinoblastoma1 tumor suppressor rb1. Sci Rep (2015) 0.80

In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models. Mol Ther (2017) 0.79

Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med (2016) 0.77

Tissue-specific tumorigenesis: context matters. Nat Rev Cancer (2017) 0.77

Somatic Engineering of Oncogenic Chromosomal Rearrangements: A Perspective. Cancer Res (2016) 0.77

The CRISPR revolution and its impact on cancer research. Swiss Med Wkly (2015) 0.77

Somatic mutations in disorders with disrupted brain connectivity. Exp Mol Med (2016) 0.76

Generation of genetically modified mice using CRISPR/Cas9 and haploid embryonic stem cell systems. Dongwuxue Yanjiu (2016) 0.75

Chd7 is indispensable for mammalian brain development through activation of a neuronal differentiation programme. Nat Commun (2017) 0.75

In Vivo Delivery Systems for Therapeutic Genome Editing. Int J Mol Sci (2016) 0.75

Somatic Mutations in TSC1 and TSC2 Cause Focal Cortical Dysplasia. Am J Hum Genet (2017) 0.75

"CRISPR" validation of recessive brain cancer genes in vivo. Oncotarget (2015) 0.75

Brain tumor modeling using the CRISPR/Cas9 system: state of the art and view to the future. Oncotarget (2016) 0.75

The application of CRISPR technology to high content screening in primary neurons. Mol Cell Neurosci (2017) 0.75

The big bang of genome editing technology: development and application of the CRISPR/Cas9 system in disease animal models. Dongwuxue Yanjiu (2016) 0.75

piggyBac mediates efficient in vivo CRISPR library screening for tumorigenesis in mice. Proc Natl Acad Sci U S A (2017) 0.75

CNS Tumors in Neurofibromatosis. J Clin Oncol (2017) 0.75

Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells. Oncogene (2017) 0.75

CRISPR/Cas9: Transcending the Reality of Genome Editing. Mol Ther Nucleic Acids (2017) 0.75

Development of zebrafish medulloblastoma-like PNET model by TALEN-mediated somatic gene inactivation. Oncotarget (2017) 0.75

Articles cited by this

Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53

RNA-guided human genome engineering via Cas9. Science (2013) 48.29

A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science (2012) 48.17

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09

TM4: a free, open-source system for microarray data management and analysis. Biotechniques (2003) 38.02

SeqMap: mapping massive amount of oligonucleotides to the genome. Bioinformatics (2008) 24.32

DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol (2013) 19.99

High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol (2013) 18.01

RNA-programmed genome editing in human cells. Elife (2013) 14.82

Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol (2013) 14.28

The somatic genomic landscape of glioblastoma. Cell (2013) 11.73

Altered neural cell fates and medulloblastoma in mouse patched mutants. Science (1997) 11.44

Mouse genomic variation and its effect on phenotypes and gene regulation. Nature (2011) 10.66

A restricted cell population propagates glioblastoma growth after chemotherapy. Nature (2012) 8.88

High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol (2013) 8.40

Lessons from the cancer genome. Cell (2013) 8.12

Medulloblastoma comprises four distinct molecular variants. J Clin Oncol (2010) 8.06

Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog. Neuron (1999) 7.80

A rapid and general assay for monitoring endogenous gene modification. Methods Mol Biol (2010) 6.77

Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol (2011) 6.67

Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res (2013) 6.19

CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol (2013) 6.19

Subtypes of medulloblastoma have distinct developmental origins. Nature (2010) 5.94

PEAR: a fast and accurate Illumina Paired-End reAd mergeR. Bioinformatics (2013) 5.61

Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell (2005) 5.51

Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell (2008) 5.06

Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82

Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell (2009) 4.82

Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell (2008) 4.68

Regulation and mechanisms of mammalian double-strand break repair. Oncogene (2003) 4.43

CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell (2014) 3.68

Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res (2001) 3.30

CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature (2014) 3.28

Medulloblastomics: the end of the beginning. Nat Rev Cancer (2012) 3.01

Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma. Development (2005) 2.97

In vivo electroporation in the embryonic mouse central nervous system. Nat Protoc (2006) 2.85

Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell (2014) 2.57

A mammalian helix-loop-helix factor structurally related to the product of Drosophila proneural gene atonal is a positive transcriptional regulator expressed in the developing nervous system. J Biol Chem (1995) 2.31

A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell (2012) 2.15

An animal model of MYC-driven medulloblastoma. Cancer Cell (2012) 2.12

A powerful nonviral vector for in vivo gene transfer into the adult mammalian brain: polyethylenimine. Hum Gene Ther (1996) 1.91

Pleiotropic role for MYCN in medulloblastoma. Genes Dev (2010) 1.84

The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched. Cancer Res (2000) 1.62

Stable integration and conditional expression of electroporated transgenes in chicken embryos. Dev Biol (2007) 1.60

Ontogeny-recapitulating generation and tissue integration of ES cell-derived Purkinje cells. Nat Neurosci (2010) 1.26

Spatiotemporal expression patterns of Pax6 in the brain of embryonic, newborn, and adult mice. Brain Struct Funct (2012) 0.99

Cell of origin for malignant gliomas and its implication in therapeutic development. Cold Spring Harb Perspect Biol (2015) 0.85

The 2000 World Health Organization classification of tumours of the nervous system. J Clin Neurosci (2001) 0.77